Login to Your Account

Mirati seeks needle move in NSCLC with sitravatinib

By Marie Powers
News Editor

Friday, September 15, 2017

Shares of Mirati Therapeutics Inc. doubled at their opening Friday morning and spiked to a 15-month high of $12.40 on word that the combination of the company's TKI, sitravatinib, with Opdivo showed three confirmed PRs in the first 11 evaluable patients with NSCLC who had progressed following checkpoint therapy.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription